✓After hours - Last update: Nov 10, 2026, 10:14 AM ET
⚠️Material / Earnings✓High confidence
Source: earnings_events
Changes History →Market closed · After hours · 6:09 PM ET
Last update: Nov 10, 2026, 5:21 PM ETMarket closed·86 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
✓After hours - Last update: Nov 10, 2026, 4:38 PM ET
🏆Material / Earnings✓High confidence
What changed: Mercury Systems, Inc. (MRCY) reported EPS of $0.52 vs. $0.30 consensus estimate for Q1 FY2027, beating by 74.7% on 2026-11-10.
Source: earnings_events
Changes History →What's next
What to watch
Upcoming guidance or forward commentary from management on Q2 FY2027 and full-year expectations.
✓After hours - Last update: Nov 10, 2026, 4:38 PM ET
🏆Material / Earnings✓High confidence
What changed: Silicon Laboratories Inc. (SLAB) reported EPS of $1.05 vs. consensus estimate of $0.84, beating by 24.3% on 2026-11-10.
Source: earnings_events
Changes History →What's next
What to watch
SLAB's next earnings are scheduled for 2027-02-03 with consensus EPS estimate of $0.81.
✓After hours - Last update: Nov 10, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: Rocket Lab USA, Inc. (RKLB) moved +14.04% from $54.99 to $62.71 on 2026-11-10, one day after reporting Q3 earnings that missed consensus. On 2026-11-09, RKLB reported EPS of −$0.12 versus an estimate of −$0.07, a 79.51% miss driven by a $27.26 million debt extinguishment loss and $21.34 million in Iridium transaction costs. Management also delayed the Neutron rocket's first flight to 2027 (from Q4 2026 target) and non-GAAP gross margins compressed to 38.4% from 41.9%. Initial pre-market selling pressure reversed as dip-buyers stepped in, with the stock recovering sharply through the session.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Rocket Lab's next earnings are scheduled for 2027-02-25; consensus EPS estimate is −$0.01.
✓After hours - Last update: Nov 10, 2026, 10:08 AM ET
🏆Material / Earnings✓High confidence
What changed: Venture Global, Inc. (VG) reported EPS of $0.96 vs. $0.50 consensus estimate for Q3 FY2026, beating consensus by 91.2%.
Source: earnings_events
Changes History →What's next
What to watch
Monitor VG's Q4 FY2026 guidance and full-year 2026 outlook for confirmation of sustained earnings power.
✓After hours - Last update: Nov 10, 2026, 4:38 PM ET
🛡Material / Earnings✓High confidence
What changed: Sanmina Corporation (SANM) moved −5.77% from $164.95 to $155.43 on 2026-11-10, the day after reporting Q4 FY2026 results that beat consensus by 35.47% (non-GAAP diluted EPS of $4.43 vs. $3.27 estimate) and raised FY2027 guidance to $15.50–$17.50 EPS and $17.5–$19.5 billion revenue. Volume traded at 2.8× the 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor for any analyst commentary on the valuation following the beat, and track commentary on AI demand sustainability and ZT Systems integration execution ahead of the next earnings date scheduled for 2027-01-25.
✓After hours - Last update: Nov 10, 2026, 4:38 PM ET
⚠️Material / Earnings✓High confidence
What changed: Rigetti Computing, Inc. (RGTI) reported EPS of −$0.06 vs. −$0.05 consensus estimate for Q3 FY2026 on November 10, 2026, missing by 15.4%.
Source: earnings_events
Changes History →What's next
What to watch
Q4 FY2026 earnings guidance and any updates on revenue trends or operating expense management.
✓After hours - Last update: Nov 10, 2026, 4:38 PM ET
⚡Material / Earnings✓High confidence
What changed: GE Vernova Inc. (GEV) moved +5.49% from $755.53 to $797.04 on 2026-11-10. The move followed a +7.6% jump on November 9 and occurred as the AI power sector broadly cooled. No company-specific news catalyst was identified; the gain appears to be a technical rebound after profit-taking pressured the stock earlier in the session, with volume near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
GEV earnings are scheduled for 2026-01-27 with a consensus EPS estimate of $6.89; monitor for updates on order book strength, wind division performance, and data center demand visibility.
✓After hours - Last update: Nov 10, 2026, 4:51 PM ET
⚡Material / Earnings✓High confidence
What changed: Range Resources Corporation (RRC) moved +5.57% from $48.50 to $51.20 on 2026-11-10. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move was not accompanied by unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Range Resources Corporation is expected to report earnings on 2027-02-23 with a consensus EPS estimate of $1.06.
✓After hours - Last update: Nov 10, 2026, 4:50 PM ET
🛡Material / Earnings✓High confidence
What changed: Cogent Biosciences, Inc. (COGT) moved -5.44% from $33.46 to $31.64 on 2026-11-10. The decline followed the company's November 5 Q3 earnings report, which posted a net loss of $111.4 million (-$0.59 EPS) that missed consensus estimates of -$0.56 EPS by 5.4%, and CEO commentary at the Guggenheim Healthcare Innovation Conference on November 10 reiterating that the company is days away from potential FDA decisions on its lead drug bezuclastinib. Elevated general and administrative expenses ($42.1 million) tied to commercial readiness and profit-taking ahead of regulatory catalysts contributed to the weakness.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
FDA decision on bezuclastinib and Cogent's next earnings report scheduled for 2027-02-16 (consensus EPS estimate -$0.60).
✓After hours - Last update: Nov 10, 2026, 4:44 PM ET
⚡Material / Earnings✓High confidence
What changed: Core Scientific, Inc. (CORZ) moved +5.46% from $12.45 to $13.13 on 2026-11-10, following momentum from recent major catalysts: Q3 colocation revenue surged 60% sequentially to $215.4M and adjusted EBITDA more than tripled to $134M. Citizens analyst Greg Miller reiterated a Market Outperform rating with a $30.00 price target, citing accelerated earnings visibility through 2027–2028 as data center contracts with CoreWeave and AMD come online. The company is transitioning away from Bitcoin mining—to be fully wound down by end-Q4 2026—toward pure-play AI colocation infrastructure.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
CORZ earnings scheduled for 2026-11-11 (consensus EPS estimate −$0.03).
✓After hours - Last update: Nov 10, 2026, 4:43 PM ET
🛡Material / Earnings✓High confidence
What changed: Bruker Corporation (BRKR) moved -6.42% from $66.51 to $62.24 on November 10, 2026. The pullback followed a 52-week high reached the previous day, after BRKR had beaten Q3 consensus on November 4 (reporting EPS of $0.56 vs. $0.42 expected and revenue of $874 million). News reports attributed the decline to profit-taking after the recent rally, institutional selling pressure revealed in Form 13F filings, and valuation concerns given the stock's run from the low $30s earlier in 2026. Organic revenue growth was modest at 0.7%, and results included a $175 million non-cash goodwill impairment.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
BRKR's next earnings are scheduled for February 11, 2027, with consensus EPS estimate of $0.77.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisNovember 10, 2026 · 11 min read
Hims & Hers (HIMS) Drops ~18% as Q3 Gross Margin Craters on the GLP-1 Shift
Hims & Hers fell about 18% to roughly $18.76 on November 10 — a seven-month low — after third-quarter results that grew revenue 49% to about $890 million but exposed a margin problem underneath. Gross margin collapsed to about 57% from 74% a year earlier, the company swung to a $33 million GAAP net loss (about $0.14 a share, versus a profit expected) even as adjusted EBITDA stayed positive, and it cut its full-year adjusted-EBITDA guidance to roughly $257–$277 million, from $275–$325 million — its third reduction this year. The culprit is the same thing that made HIMS a market darling: weight-loss drugs. As the era of cheap compounded GLP-1 medications wound down, Hims pivoted to selling branded drugs, which are a low-margin, pass-through business, so the mix shift that keeps revenue growing — led by its international rollout — is compressing margins. (A just-announced deal to distribute Eli Lilly's Zepbound, unveiled after the quarter closed, lifted the stock Friday but postdates these results.) Subscribers also disappointed, rising 13% to about 2.79 million but below the roughly 3.04 million expected and down about 100,000 sequentially, with management flagging more weakness. The move was company-specific: telehealth peers were roughly flat, the market barely moved, and Eli Lilly, the drug supplier, actually rose. Wall Street is lukewarm — a Hold consensus, with brokers cutting targets toward the mid-$20s on the print, though still above the price. After a 50%-plus decline the stock trades at under two times sales, which looks cheap only if margins and subscribers stabilize — the very things that just deteriorated.
HIMSRead →
Stock AnalysisNovember 9, 2026 · 12 min read
QXO (QXO) Jumps ~20% as the TopBuild Deal Lifts Q3 Sales 79%
QXO jumped about 20% to roughly $13.90 on November 9 after the building-products distributor released preliminary third-quarter results ahead of its full report. Net sales rose about 79% to $4.9 billion and adjusted EBITDA rose about 85% to $557 million, with the margin edging up to 11.4% — modestly ahead of the roughly $4.85 billion revenue consensus. QXO is the building-products roll-up of Brad Jacobs, who previously built XPO Logistics and United Rentals, and this was its first full quarter including TopBuild, the insulation installer and distributor it bought on July 1 for about $15 billion. So the 79% sales jump is mostly acquired, not organic — the scale of acquisitions landing in the numbers for the first time, though management pointed to improving organic sales trends and firmer pricing on a separate call. What the market rewarded was the margin signal — EBITDA growing faster than sales as a giant deal is absorbed — the clearest early sign the integration is working, against a stock that had fallen roughly 19% over the past year. The caveats are important: these are preliminary, unaudited figures (full results come November 12); the growth is acquisition-driven and the release gave no consolidated organic rate; QXO is still a GAAP loss-maker because of acquisition amortization, interest and deal costs; and the expansion is financed with heavy share issuance (the count is up about 60% in a year) and roughly $7 billion of debt. The move was company-specific — QXO far outpaced building-products peers that rose only mid-single digits. Analysts keep a Strong Buy with an average target near $24, though several had trimmed targets into the quarter. The real verdict waits for the full results.
QXORead →
Stock AnalysisNovember 9, 2026 · 12 min read
Ionis (IONS) Drops ~24% After a Q3 Beat on a Halved TRYNGOLZA Forecast
Ionis Pharmaceuticals fell about 24% to roughly $29.80 on November 9 — and traded as low as $27.75, a fresh 52-week low — even though its third quarter beat: revenue of $243 million topped the roughly $178 million expected, and the GAAP loss of $0.66 a share was narrower than feared. The stock cratered on a guidance cut, not the quarter. Ionis roughly halved its full-year 2026 sales forecast for TRYNGOLZA, its homegrown drug for high triglycerides, to about $50 million from a prior $100–$110 million, citing a slower-than-expected launch ramp (third-quarter TRYNGOLZA sales were just $9 million). Because TRYNGOLZA is the centerpiece of Ionis's transition from a royalty-and-partnership company into one that sells its own drugs, halving its forecast dented the core thesis and pushed the company's path to sustained positive cash flow out about a year, toward 2029. Crucially, this was not a company-wide cut: Ionis left total 2026 revenue guidance unchanged at $875–$900 million, kept cash guidance steady (about $1.9 billion at quarter-end), and reaffirmed its other launched drug, DAWNZERA. The move was clearly company-specific — on the same day the RNA peer Alnylam was flat, the biotech ETF XBI rose about 2% and the S&P 500 rallied. Wall Street mostly treated it as a timing reset, reiterating Buy ratings and leaving an average target near $84, more than double the price. The whole debate is now the slope of the TRYNGOLZA sales line.
IONSRead →
Stock AnalysisOctober 30, 2026 · 12 min read
Reddit (RDDT) Crashes ~30% After a Q3 Beat on a Google AI Search-Traffic Warning
Reddit crashed about 30% to roughly $90.79 on October 30 — a striking reaction, because the quarter itself was strong: revenue of $895 million rose 53% year over year, a clear beat, with net income of $283 million, diluted EPS of $1.40 and adjusted EBITDA of $402 million. The stock cratered on what management said about the future. On the earnings call, CEO Steve Huffman warned that search referrals fell more than a million per week on average in October as Google answers more queries with AI, and that daily active users (around 130 million) could fall a low-double-digit percentage in the fourth quarter if the trend held. Investors also fixed on a 2% year-over-year decline in US daily actives — Reddit's most valuable market, where revenue per user is more than five times the international level — and on fourth-quarter revenue guidance of $1.00–$1.03 billion that came in below expectations; Citizens downgraded the stock before the open. The one bullish counterweight was monetization: revenue per user still jumped 36% globally. The move was company-specific — Reddit's roughly 30% drop was about four times the moves of social peers Snap and Pinterest (each down ~7%), on a day the broad market fell about 2%. After the crash Reddit trades at roughly 14 times forward earnings with about $3 billion of net cash — not expensive for 50%-plus growth, if the growth is durable. The whole debate is whether rising revenue per user can keep outrunning a top of the funnel that AI search is draining.
RDDTRead →
Stock AnalysisOctober 20, 2026 · 10 min read
General Motors (GM) Falls ~8% Despite a Q3 Beat and a $20B Buyback
General Motors fell about 8% to roughly $75.77 on October 20 — a striking reaction, because GM beat on third-quarter earnings, raised its full-year profit outlook and announced a $20 billion buyback. Adjusted earnings of $3.70 a share topped estimates on revenue of about $50 billion, and GM lifted the midpoint of its full-year adjusted-EPS guidance to about $13.25 (from $13.00) and raised its free-cash-flow outlook. The stock fell anyway on what the guidance implied, not the quarter. The full-year outlook implies a softer fourth quarter — only about $2.7 billion of operating profit versus $4.1 billion in the third, as a Silverado/Sierra redesign temporarily cuts truck deliveries by roughly 35,000 units — the raised $13.25 EPS midpoint still landed just below the roughly $13.41 the Street expected, and management flagged about $2 billion of 2026 cost inflation plus a conditional scenario of more in 2027. Two things that look like culprits mostly were not: the 62% drop in EV sales was already known and reflects a distorted 2025 comparison, and tariff costs are now expected near the low end of an existing range. Crucially, GM did not cut its 2027 outlook — it still expects next year to improve if conditions hold. The move was clearly company-specific — Ford fell only about 1%, Stellantis was flat and the S&P 500 rose — so this was a repricing of GM's forward earnings, not an auto-sector sell-off. The valuation captures the tension: GM trades at barely five to six times the forward earnings it guides to, extraordinarily cheap, because the market prices automakers for the downturn, not the peak. A $20 billion buyback into that multiple is powerfully accretive if earnings hold — but whether they hold in 2027 is exactly the question. Analysts keep a Buy consensus and an average target near $104.
GMRead →
Stock AnalysisOctober 19, 2026 · 10 min read
Summit Therapeutics (SMMT) Jumps ~6% on a New Ivonescimab Kidney-Cancer Trial
Summit Therapeutics rose about 6% to roughly $15.57 on October 19 after announcing it had opened a global Phase II trial of ivonescimab — its closely watched lead drug — in previously untreated advanced clear cell kidney cancer, with partner Akeso. The key nuance: this is the opening of a mid-stage study, not a data readout, so it is an incremental catalyst that expands the story rather than one that proves it. Summit is effectively a one-drug company: ivonescimab is a PD-1/VEGF bispecific antibody, licensed from China's Akeso, that outperformed Merck's Keytruda in a Chinese lung-cancer trial — nearly doubling progression-free survival and, in updated data, delivering a significant overall-survival benefit (30.8 vs 22.6 months) — though the global trial behind its U.S. filing has yet to formally confirm that survival benefit in Western patients. With no product revenue and a market value above $12 billion, essentially all of Summit's worth is the market's bet on that drug, so a new indication is a fresh call option on the thesis. Two bigger items frame it: AstraZeneca agreed in late September to invest about $2 billion in Summit equity (a ~12% stake), transforming the balance sheet and removing the financing overhang, and the FDA has a November 14, 2026 decision date on ivonescimab in EGFR-mutated lung cancer — a near-term, binary catalyst that matters far more than a trial start. Monday's move was partly company-specific and partly a tailwind: biotech broadly rallied, with the sector ETF up about 2.5%, but Summit outperformed. The risks are a binary valuation on one molecule, an unconfirmed Western survival benefit, and a stock down roughly 47% from its high. Analysts carry a Buy consensus and an average target near $30, inside a wide range from about $12 to the mid-$40s.
SMMTRead →